Women and babies are dying from inertia: a collaborative framework for obstetrical drug development is urgently needed

Obstetrical complications, often referred to as the “great obstetrical syndromes,” are among the most common global causes of mortality and morbidity in young women and their infants. However, treatments for these syndromes are underdeveloped compared with other fields of medicine and are urgently needed. This current paucity of treatments for ob stetrical complications is a reflection of the challenges of drug development in pregnancy. The appetite of pharmaceutical companies to invest in research for obstetrical syndromes is generally reduced by concerns for maternal, fetal, and infant safety, poor definition, and high-risk regulatory path s toward product approval.

Source: American Journal of Obstetrics and Gynecology - June 30, 2021 Category: OBGYN Authors: Edith Roset Bahmanyar, Henk J. Out, Marcel van Duin Tags: Clinical Opinion Source Type: research